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Abstract
Background and Aims: The genes encoding for tumor
necrosis factor-· (TNF-·), epidermal growth factor recep-
tor (EGFR) and the vitamin D receptor (VDR) are colocal-
ized to inflammatory bowel disease-associated linkage
regions on chromosomes 6, 7 and 12. An association
study of these gene polymorphisms with ulcerative coli-
tis or Crohn’s disease and a stratification according to
disease phenotypes was performed in order to identify
gentically homogenous subgroups. Patients and Meth-
ods: 119 healthy, unrelated controls, 95 patients with
Crohn’s disease and 93 patients with ulcerative colitis
were genotyped for the (G to A) –308 TNF-· promoter
polymorphism on chromosome 6, the codon 497 EGFR
polymorphism on chromosome 7 and the TaqI polymor-
phism of the VDR gene on chromosome 12. After geno-
typing, patients were stratified according to the respec-
tive disease phenotype. Results: A disequilibrium in the
distribution of the VDR genotypes was found in patients
with ulcerative colitis compared to controls (p = 0.024). In
fistulizing and fibrostenotic Crohn’s disease the ‘TT’ ge-
notype was significantly reduced compared with other
phenotypes (p = 0.006), whereas the ‘tt’ genotype was
found more frequently (p = 0.04). The frequency of the
WT allele of the EGFR gene was significantly higher in
ulcerative colitis (p = 0.04) than in controls. Further signif-
icant differences, concerning the associations of the dif-
ferent polymorphisms and disease susceptibility or clini-
cal phenotypes, were not observed. Conclusions: Re-
gardless of the disease phenotype, the associations be-
tween the polymorphisms and inflammatory bowel dis-
ease investigated herein are modest, even after stratifi-
cation for the disease phenotypes. Hence, these poly-
morphisms are unlikely to confer the reported linkage
between inflammatory bowel disease and chromo-
somes 6, 7 and 12.
Copyright © 2002 S. Karger AG, Basel
Introduction
One of the most attractive hypotheses concerning the
etiology of inflammatory bowel disease comprises an
aberrant regulation of the mucosal immune response
which probably results in a loss of the immune tolerance
against luminal antigens. Thus, genes involved in the reg-
ulation of the immune response and intestinal mucosal
repair and defense are apparently candidates for genetic
studies. Genome wide linkage analyses in large patient
cohorts of different ethnic backgrounds have defined
inflammatory bowel disease susceptibility loci located on
chromosomes 3, 6, 7, 12 and 16 employing microsatellite
markers in affected relative pairs [1–13], although linkage
could not be confirmed by every group [7, 14, 15].
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The tumor necrosis factor-· (TNF-·) gene is located on
chromosome 6 within the HLA class III region, telomeric
to the class II and centromeric to the class I region. Link-
age of inflammatory disease has been demonstrated re-
cently to this region which is situated on the short arm of
chromosome 6 [4]. The biallelic G to A transition poly-
morphism located at position –308 in the TNF promoter
region defines the TNF1 (-308G) and the TNF2 (-308A)
alleles [16]. Elevated circulating levels of TNF-· were
described in individuals homozygous for TNF2 [17].
Epidermal growth factor receptor (EGFR) is a 170-
kDa transmembrane glycoprotein which mediates the
effects of epidermal growth factor (EGF) and transform-
ing growth factor -· (TGF-·). EGF enhances host natural
defenses against mucosal injury by creating a dilutional
barrier that restricts injury from caustic agents [18]. In
animal models of colitis a marked increase in EGFR
immunoreactivity has been noted [19], suggesting a role
for EGF in intestinal mucosal repair and defense. Moriai
et al. [20] identified a G to A transition at codon 497 of
the EGFR resulting in an arginine to lysine substitution.
The human EGFR maps to chromosome 7p12, a region
which has been linked to inflammatory bowel disease [1].
The gene encoding for the vitamin D receptor (VDR) is
situated within 3 cM to the microsatellite marker D12S85
on chromosome 12, which has been linked to ulcerative
colitis and Crohn’s disease by different groups [1, 3, 5,
21]. Vitamin D3 affects calcium hemostasis and exhibits
distinct immunomodulatory effects, by activating macro-
phages and monocytes and suppressing lymphocyte pro-
liferation and immunoglobulin production [22, 23]. The
proinflammatory transcription factor NFÎB is inhibited
by vitamin D3 and subsequently the expression of proin-
flammatory cytokines is impaired [24].
The present study sought to address whether immu-
norelevant genes colocalized to previously described link-
age regions are associated with inflammatory bowel dis-
ease. In addition, a stratification of the respective poly-
morphisms according to the disease phenotypes was per-
formed in order to identify genetically homogenous sub-
groups.
Methods
Study Population
Blood samples were obtained from 95 patients with Crohn’s dis-
ease (male:female ratio 33:62; age 40 B 14 years), 93 patients with
ulcerative colitis (male:female ratio 41:52; age 43 B 14 years), and
119 healthy, unrelated controls. The diagnosis of Crohn’s disease and
ulcerative colitis and the respective disease phenotype, e.g. fistuliz-
ing, fibrostenotic, were assessed by conventional clinical, endoscop-
ic, histopathological and radiologic criteria. Patients were recruited
consecutively between 1986 and 2000 (urban, middle European pop-
ulation).
DNA Extraction
Genomic DNA was prepared from buffy coat layers employing a
commercially available kit (QIAamp DNA Blood Mini Kit; Quiagen,
Hilden, Germany).
Determination of the TNF-· Genotype
Two allelic forms were genotyped, referred to as TNF1 and
TNF2, that are identical apart from a single base transition (G to A)
at –308 of the TNF-· promoter. Typing was performed by PCR
amplification using the primers as previously described [25]. The
primer pair C1 5)-TCTCGGTTTCTTCTCCATCG-3) was used in
combination with either the primer C2 5)-TAGGTTTTGAGGGG-
CATGG-3) for amplifying TNF1 or the 5) primer C3 5)-ATAGG-
TTTTGAGGGGCATGA-3) for amplifying the 184-bp TNF2 frag-
ment. The primer pair GAPDHse/GAPDHas producing a 310-bp
fragment out of the GAPDH gene was added to each reaction as an
internal control. The 184-bp fragment of the TNF-· promoter region
was amplified by a 32-cycle PCR with a hot start Taq polymerase
(HotStarTaq DNA Polymerase, Qiagen GmbH) employing a Biome-
tra-Thermocycler (Biometra, Göttingen, Germany). PCR was car-
ried out under standard conditions. Annealing was performed for
60 s at 60°C. PCR products were analyzed using a 2% agarose gel
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany).
EGFR (or HER) Polymorphism
Primer sequences 5)-GTTTGGGACCTCCGGTCAG-3) and 5)-
CTTGTCCACGCATTCCC TGC-3) spanning the BstNI restriction
site were identical to those described by Moriai et al. [20]. For PCR
amplification (Cycler and Taq as above), standard conditions were
used (annealing temperature 59 °C for 1 min, 35 cycles). 20 Ìl of the
102-bp PCR product was digested with BstNI (New England Biolabs)
at 65°C for 2 h. Alleles were separated on 4% NuSieve ethidium
bromide-stained gels. In the case of a homozygous wild-type individ-
ual, one undigested 102-bp band was obtained. The G to A transition
at codon 497 created a BstNI restriction site so that three bands (102,
54 and 48 bp) were present in heterozygous individuals. If a patient
had a homozygous transition, only the 54- and the 48-bp band were
seen.
Analysis of the Vitamin-D Receptor Genotype
Sequence-specific primers were used for typing the biallelic VDR
polymorphism as described elsewhere [26]. The consensus primer 5)-
CAGAGCATGGACAGGGAGC-3) was either used with primer T
5)-CGGTCCTGGATGGCCTCA-3) giving rise to the T allele or the
primer t 5)-CGGTCCTGGATGgCCTCG-3) for amplifying the 310-
bp t fragment. As an internal control the primer pair F/R was added
to each reaction producing a 700-bp fragment out of the GAPDH
gene. At an annealing temperature of 66 °C for 50 s, PCR was per-
formed under standard conditions. PCR products were also visual-
ized in 2% agarose gel.
Statistical Analysis
Statistical evaluation was performed by use of the Fisher’s exact
test.
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Results
The genotype frequencies of the three polymorphisms
investigated herein are depicted in table 1. The frequen-
cies of the VDR genotypes in ulcerative colitis were found
in significant disequilibrium (p = 0.024): The ‘Tt’ geno-
type was found less frequent (41 vs. 58%), whereas the ‘tt’
genotype was more prevalent when compared to controls
(29 vs. 16%). The frequency of the WT allele in the EGFR
Table 1. Genotype frequencies in the different groups of the study
population
Controls Crohn’s disease
95 patients
Ulcerative colitis
93 patients
TNF-·
TNF1/TNF1
TNF1/TNF2
87 (73%)
32 (27%)
78 (82%) n.s.
17 (18%)
74 (80%) n.s.
19 (20%) 
EGFR
WT/WT
WT/EGFR2
EGFR2/EGFR2
62 (52%)
47 (39%)
10 (9%)
50 (53%) n.s.
37 (39%) n.s.
8 (8%) n.s.
60 (65%) n.s.
30 (32%) n.s.
3 (3%) n.s.
VDR
T/T
T/t
t/t
31 (26%)
69 (58%)
19 (16%)
37 (39%) n.s.
45 (47%)
13 (14%)
28 (30%) p = 0.024
38 (41%)
27 (29%) 
TNF1 = Wild-type allele , TNF2 = G to A transition, WT = wild-
type, T = wild-type allele, t = A to C substitution, n.s. = not signifi-
cant.
gene was increased in ulcerative colitis (p = 0.04). Further
significant differences concerning the frequency of the
TNF-· and the EGFR polymorphism between patients
and controls were not observed (see table 2).
The frequencies of the different polymorphisms which
were observed after stratification according to the disease
phenotype in Crohn’s disease are listed in table 3. The
‘TT’ genotype shared a negative and the ‘tt’ a positive
association with the fistulizing and fibrostenotic pheno-
type (p = 0.006 and 0.04, respectively). Further significant
differences in the genotype distribution were not observed
after stratification with regard to clinical phenotypes.
Discussion
Inflammatory bowel diseases are heterogeneous with
respect to clinical behavior, response to medical treat-
ment and prognosis. The concept of genetic heterogeneity
in inflammatory bowel disease is supplied by several
observations [27, 28]. In accordance with this concept an
appropriate understanding of the etiology of inflammato-
ry bowel disease will only be possible after stratification of
patients according to clinical or genetic markers in order
to identify genetically homogenous subgroups.
TNF-· is a proinflammatory cytokine of paramount
importance in inflammatory bowel disease. Increased
concentrations of TNF-· were described in serum [29],
stool [30] and the intestinal mucosa of patients with
Crohn’s disease [31, 32]. The administration of anti-
TNF-· antibodies has profound effects in active Crohn’s
disease [33–35]. The individual variations in TNF-· pro-
Table 2. Allele frequency in the different
groups of the study population Controls Crohn’s disease
95 patients/190 alleles
Ulcerative colitis
93 patients/186 alleles
TNF-·
TNF1 allele
TNF2 allele
206/238 (87%)
32/238 (13%)
173/190 (91%) n.s.
17/190 (9%)
167/186 (90%) n.s.
19/ 186 (10%)
EGFR
WT allele
EGFR2 allele
171/238 (72%)
67/238 (28%)
137/190 (72%) n.s.
53/190 (28%)
150/186 (81%) p = 0.04
36/186 (19%)
VDR
T allele
t allele
131/238 (55%)
107/238 (45%)
119/190 (63%) n.s.
71/190 (37%)
94/186 (51%) n.s.
92/186 (49%)
TNF1 = Wild-type allele , TNF2 = G to A transition, WT = wild-type, EGFR2 = G to A
transition, T = wild-type allele, t = A to C substitution, n.s. = not significant.
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Table 3. Genotype frequencies according to the disease phenotype in Crohn’s disease
Fistulizing
15 patients
Stenotic
24 patients
Fistulizing + stenotic
40 patients
Nonfistulizing, nonstenotic
16 patients
TNF-·
TNF1/TNF1 11 (73%) n.s. 20 (83%) n.s. 35 (88%) n.s. 12 (75%) n.s.
TNF1/TNF2 4 (27%) 4 (17%) 5 (13%) 4 (25%)
EGFR
WT/WT 10 (67%) n.s. 14 (58%) n.s. 19 (48%) n.s. 7 (44%) n.s.
WT/EGFR2 4 (27%) n.s. 8 (33%) n.s. 16 (40%) n.s. 9 (56%) n.s.
EGFR2/EGFR2 1 (7%) n.s. 2 (8%) n.s. 5 (13%) n.s. 0 n.s.
VDR
T/T 7 (47%) n.s. 13 (54%) n.s. 9 (23%) p = 0.006 8 (50%) n.s.
T/t 7 (47%) n.s. 9 (38%) n.s. 22 (55%) n.s. 7 (44%) n.s.
t/t 1 (7%) n.s. 2 (8%) n.s. 9 (23%) p = 0.040 1 (6%) n.s.
TNF1 = Wild-type allele, TNF2 = G to A transition,WT = wild-type, EGFR2 = G to A transition, T = wild-type
allele, t = A to C substitution, n.s. = not significant. p values vs. controls.
duction are likely to be caused by regulatory polymor-
phisms in or near the TNF-· gene, such as the polymor-
phism at position –308 in the TNF promoter region. Sev-
eral groups have shown that the TNF2 allele polymor-
phism is associated with increased transcription factor
binding as well as increased transcriptional activity com-
pared to the TNF1 allele [36–38]. This correlates with
increased circulating concentrations of TNF-· in individ-
uals homozygous for TNF2, as compared to individuals
homozygous for TNF1, whereas heterozygous individuals
display intermediate levels of TNF-· [17]. However, in
contrast to previously reported data [39, 40], we were
unable to detect an association between the –308 TNF-·
polymorphism and ulcerative colitis or Crohn’s disease.
Such an association was also not observed after stratifica-
tion according to the clinical phenotype in Crohn’s dis-
ease.
Exogenous administration of EGF significantly re-
duces the mucosal damage and inflammation induced in
animal models of colitis [41]. Although the mechanism by
which EGF provides protection is currently unknown, it
has been postulated that through its ability to stimulate
mucin glycoprotein synthesis and secretion [42–44], EGF
enhances host natural defenses against mucosal injury by
creating a dilutional barrier, that restricts injury from
caustic agents [18]. EGFR might therefore play an impor-
tant role in intestinal mucosal repair and defense. In
1993, a variant EGFR was identified that had an arginine
to lysine substitution at codon 497 [20]. Wild-type EGFR
differs in contrast to mutant EGFR with respect to epithe-
lial proliferation following the administration of EGF and
TGF-· in rodents [45]. Thus, it is appears possible that
mutations which influence the function or expression of
EGFR might predispose to inflammatory bowel disease.
A slight but significant association between the WT allele
and ulcerative colitis was found. Further associations
regarding the genotype or disease phenotype were not
observed.
The immunoregulating effects of the cellular receptor
for 1,25(OH)2 vitamin D3 are complex and not yet finally
understood. The TaqI polymorphism, located at the 3)
end of the VDR gene, has been associated with bone min-
eral density and osteoporosis in a number of different
populations [46], as well as with the risk of prostate cancer
[47]. The ‘tt’ genotype of the TaqI polymorphism seems to
predispose to a variety of infectious diseases, such as
tuberculosis, chronic hepatitis B and leprosy [48–50].
Since the TaqI polymorphism does not result in an amino
acid coding change (it is an A to C base substitution at
codon 352 of exon 8, both isoleucine), the mechanism of
how the polymorphism might affect disease susceptibility
remains unclear. In addition, the data reflecting the func-
tional significance of the TaqI polymorphism are contra-
dictory [51]. Under the assumption that the ‘tt’ genotype
is associated with enhanced VDR transcription, a stron-
ger cell-mediated immune response with increased mac-
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rophage or monocyte activation could predispose to in-
flammatory bowel disease. Furthermore, an impaired
mucosal antibody secretion resulting in increased suscep-
tibility to bacterial infection which could trigger inflam-
matory bowel disease. In contrast to previously reported
data [26], we were unable to detect a positive association
between the ‘tt’ genotype and Crohn’s disease, instead we
found a disequilibrium in the distribution of the VDR
genotypes in ulcerative colitis. Compared to the controls,
the ‘Tt’ genotype was less frequent in patients with ulcer-
ative colitis, whereas the ‘tt’ genotype was found more
often. After stratification of patients with Crohn’s disease
regarding the clinical phenotype, we found a negative
association of the ‘TT’ genotype, as well as a positive asso-
ciation of the ‘tt’ genotype with the fistulizing and fibro-
stenotic phenotype. However, concerning the conflicting
nature of the data and the weakness of the associations, it
appears unlikely that the TaqI polymorphism of the VDR
gene is an important determinant of disease suscepti-
bility.
In summary, with the exception of the associations
between the VDR genotypes and inflammatory bowel dis-
ease and the weak association of the WT allele and the
EGFR gene, further significant associations between the
immunologically relevant gene polymorphisms which are
colocalized to previously reported linkage regions in in-
flammatory bowel disease were not observed in the
present study. Thus, it appears unlikely that linkage of
chromosomes 6, 7 and 12 with inflammatory bowel dis-
ease is due to polymorphisms of the genes investigated
herein.
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